Ten Website Elements That Build Buyer Confidence

Claims in this piece are observable and methodological — no client or benchmark data used.

A CDMO can have the right facility, the right regulatory credentials and years of relevant manufacturing experience — yet still leave a prospective buyer uncertain about what it actually does. That usually isn’t a capability problem. It is an information problem.

A buyer researching a new manufacturing partner may never have heard of the company before. They are trying to establish, quickly, whether the organisation is relevant to their requirement and credible enough to investigate further. Increasingly, that research may involve an AI assistant as well as conventional web research.

The implication for a pharmaceutical website is straightforward: the information that builds confidence has to be specific, visible and easy to establish from the outside. The parent article, Your Pharmaceutical Website Is No Longer Just a Brochure, sets out the broader argument and the four confirmations that matter — capability fit, regulatory credibility, demonstrated depth and coherence. This article applies that thinking to the website itself, as ten concrete elements worth checking.

The ten elements

• 1. Specific manufacturing capabilities. “A broad range of pharmaceutical manufacturing capabilities” is almost impossible to use as evidence. A buyer looking for sterile fill-finish needs to know whether you actually provide it. If you have lyophilisation, say so. If you manufacture oral solid dosage forms, distinguish tablets, capsules, or modified-release products where those distinctions genuinely matter. If you handle high-potency compounds, explain the relevant containment capability accurately. Specificity reduces how much interpretation the person — or system — doing the research has to supply.
• 2. Visible regulatory standing. A logo is not the same thing as an explanation. If a particular approval, certification or inspection history is commercially relevant, the website should make the fact discoverable in plain language, while keeping appropriate links to official documentation. A CDMO serving an EU-regulated programme may need to communicate different evidence from one targeting a US FDA-regulated programme. The principle is the same: don’t make an evaluator reconstruct your regulatory position from scattered clues.
• 3. Named therapeutic or technical specialisation. A capability statement tells a buyer what you can do; a specialisation statement starts to explain where you have depth. “Oncology” is more useful than “multiple therapeutic areas.” “HPAPI containment” is more useful than “specialised manufacturing solutions.” “Complex technology transfer” is more useful than “seamless project execution.” The point isn’t impressive terminology — it’s naming the areas where the company genuinely has experience, rather than claiming depth simply because a service appears somewhere in the portfolio.
• 4. Evidence of how the capability works. Buyers need enough substance to distinguish a genuine operating capability from a marketing claim. For a relevant capability, that might mean explaining the manufacturing process, facility type, technology-transfer experience, containment approach, dosage forms, or development stage — facts genuinely appropriate to disclose. Experienced pharmaceutical people notice something a marketing review can miss: a facility may have excellent equipment without the organisation having deep commercial experience applying it to the programmes a buyer cares about. The website needs to communicate that distinction.
• 5. Clear market context. A manufacturer can be perfectly capable of producing a product without being the right partner for a particular market. Where commercially relevant, make the market context understandable — regions served, relevant regulatory environments, export experience, or the markets in which the organisation is actually active. Not for SEO; to answer the buyer’s real question.
• 6. Technology-transfer capability. Technology transfer is often described as though it were simply another service. For a prospective CDMO customer, it can be a major part of the actual evaluation. If it’s a genuine strength, explain what that means in practice: does the organisation support transfer into commercial manufacturing? What aspects of the process can be described publicly and accurately? A vague statement about “seamless technology transfer” tells an evaluator very little.
• 7. Quality information that supports, rather than overwhelms. Quality is essential, but a website can easily become a wall of generic assurances. “Quality is at the heart of everything we do” tells a buyer little. The useful question is what quality-related facts an outsider can reasonably establish: relevant certifications, regulatory context, and quality systems presented clearly, without exposing controlled or commercially sensitive information. The objective isn’t the quality agreement on the homepage — it’s enough substance to show the claims have a credible foundation.
• 8. Current corporate facts. Even basic information matters. Facility locations, manufacturing scope, company identity and organisational relationships should not contradict one another across the public web. An old directory entry describing a facility differently from the current website may seem trivial internally; to someone researching from outside, it introduces uncertainty. This is where the fourth confirmation — coherence — becomes particularly important.
• 9. Pages that answer buyer questions, not just internal categories. Many pharmaceutical websites are organised around the company’s preferred structure: About Us, Our Facilities, Our Services, Quality, Contact. A buyer may instead be thinking: “Which CDMOs can handle sterile injectable technology transfer for an EU-regulated programme?” The website doesn’t need pages with those exact titles — but the underlying information needs to be present and connected well enough to answer the questions.
• 10. Consistency across the public record. This may be the least visible element, because it extends beyond the website. A company can describe itself one way on its site, another way on a corporate profile, and a third way in an old industry directory. A human buyer can ask for clarification; an AI assistant may instead produce an incomplete or uncertain description. That is why AI Visibility is not simply a website-writing exercise — it concerns how genuine company information is represented across the whole public environment.

That tenth element is the same underlying logic as Seven Trust Signals Every Pharmaceutical Website Should Demonstrate; the difference here is the commercial role those signals play during supplier discovery.

Which elements matter most to a buyer?

If a CDMO leadership team wants to review its website without commissioning a full redesign, start with the commercially important capabilities. For each one, ask: can an outsider establish the capability, the relevant regulatory context, the depth behind it, and the surrounding corporate facts — without asking us first? That’s a more useful exercise than asking whether the website looks modern. A polished site can still be commercially vague; a straightforward site can make a highly specialised manufacturer unusually easy to understand.

A simple demonstration you can run

Choose one capability that matters commercially — for example, sterile injectable manufacturing with lyophilisation for regulated export markets. Ask each of the major AI assistants the same question: “What can you establish about [Company] as a CDMO for sterile injectable manufacturing and lyophilisation? What capabilities, regulatory markets and relevant specialisations can you verify from public information?”

Repeat in ChatGPT, Gemini, Perplexity, Claude and Copilot, then compare the responses against the company’s actual website. Look for capabilities that are missing, claims that are vague, facts that are incorrect, differences between platforms, and capabilities that exist internally but are difficult to establish externally. This is an observation exercise — not proof of market position, and not a ranking test. It simply answers a useful question: what can an outside system actually establish about us?

If the answer is no, the issue may not be the business. It may be that the business has not made its strengths sufficiently legible.

The website is now part of the commercial process

A pharmaceutical website does not need more adjectives. It needs more useful evidence. For a CDMO, that means making the real business easier for an outsider to establish: what you manufacture, where your depth lies, which regulatory context matters, and whether the story remains coherent across the public record. That is the practical meaning of treating the website as more than a brochure.

Emerivo works exclusively with TPMs, CMOs, CDMOs and CROs, helping them understand and improve how ChatGPT, Gemini, Perplexity, Claude and Copilot find, interpret and describe their organisations. The AI Discovery Audit™ tests how AI assistants currently understand an organisation against realistic buyer questions — diagnostic, not a promise of rankings or recommendations. Read the parent cornerstone: Your Pharmaceutical Website Is No Longer Just a Brochure.

Frequently asked questions